Commentary

The changing face of hepatitis C in the new era of direct-acting antivirals

Vincent Soriano *, Pablo Labarga, Jose V. Fernández-Montero, Jose M. Benito,
Eva Poveda, Norma Rallon, Clara Sánchez, Eugenia Vispo, Pablo Barreiro

Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain

ABSTRACT

The approval of the first protease inhibitors as treatment for hepatitis C virus (HCV) infection is rapidly transforming the way patients with chronic hepatitis C are managed. Treatment regimens are moving to combinations given for shortened periods, excluding poorly tolerated subcutaneous interferon, and providing rates of cure exceeding 75%. The recognition of HCV infection as a systemic disease, not limited to producing liver damage, in which extrahepatic complications play a major role as the cause of morbidity and mortality, is prompting the treatment of a growing number of HCV-infected individuals. However, new challenges are emerging, including the need to diagnose a substantial proportion of asymptomatic carriers, the risk of potentially harmful drug–drug interactions and the high cost of medications. The future will probably see a progressive marginalization of residual HCV populations, with increasing over-representation of illegal immigrants, alcohol abusers, intravenous drug users and the mentally disabled.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

The US Food and Drug Administration approved boceprevir and telaprevir as treatments for chronic hepatitis C virus (HCV) infection in the spring of 2011. These two small molecules are competitive inhibitors of the NS3 viral protease. Their administration along with pegylated interferon-α plus ribavirin heralds a new era in the management of hepatitis C (Alter and Liang, 2012), somewhat resembling what happened in 1996 in the AIDS field, when the first HIV protease inhibitors were approved and triple antiretroviral combinations began to be widely used.

Triple combination therapy for hepatitis C, including either of the first two direct-acting antivirals (DAA), is currently recommended for patients infected with HCV genotype 1 (Ghany et al., 2011). In comparison with the previous regimen (dual therapy with peginterferon-α and ribavirin), overall response rates have increased from 35% to 70%, and in many subjects the length of therapy can be reduced from 12 to 6 months. The downside is that triple therapy significantly increases the patient's pill burden and side effects, and drug interactions and complicated treatment schedules require significant expertise by healthcare providers. Because the new drugs are quite expensive, curative therapy for hepatitis C cure is becoming something of a privilege for wealthy societies or individuals. However, the prospect of being able to cure most patients has prompted US public health authorities to recommend HCV testing for everyone born from 1945 to 1965 (DHHS, 2012).

2. Expanding hepatitis C treatment

The opportunity to cure most patients has increased interest in treating chronic hepatitis C beyond those with advanced liver disease. This situation resembles what has already occurred with HIV infection. For a long time, antiretroviral therapy was restricted to subjects with advanced immune deficiency. However, as the number of drugs increased, their potency enhanced and their safety improved, a larger number of HIV-infected individuals began treatment earlier. Most importantly, the benefit of antiretroviral treatment now extends beyond the correction of immune deficiency to reduce virus transmission and ameliorate the deleterious consequences of chronic inflammation caused by persistent immune activation. These effects accompany complete suppression of viral replication, even though HIV is not eradicated. For all these reasons, recent guidelines recommend treating almost everyone with HIV infection (Thompson et al., 2012).

For chronic hepatitis C, the major concern for most individuals is the development of end-stage liver disease, either decompensated cirrhosis or liver cancer, which life-long occurs in around 25% of patients. However, extrahepatic manifestations of HCV infection are common, and when possible should also prompt early treatment. These illnesses are caused by immune complexes (e.g., mixed cryoglobulinemia), or result from persistent inflammation

* Corresponding author. Address: Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain. Tel.: +34 91 4532536; fax: +34 91 7336614.

E-mail address: vsoriano@dragonet.es (V. Soriano).

and immune activation driven by continuous viral replication, resembling what happens in HIV infection. Although the appeal of preventing viral transmission is lower for HCV than for HIV, given the different efficiency of sexual transmission, the possibility of truly eradicating HCV is a unique claim (Table 1).

3. Extrahepatic manifestations of HCV infection

Table 2 summarizes the wide spectrum of dermatological, renal, neurological and cardiovascular manifestations associated with chronic HCV infection. The most common renal complication is type I membranoproliferative glomerulonephritis, usually in the context of type II mixed cryoglobulinemia. Several studies have shown that HCV infection is also associated with an increased risk of renal insufficiency or proteinuria (Peters et al., 2012).

Neurological complications ranging from peripheral neuropathy to cognitive impairment occur in a large number of HCV patients (Sarkar et al., 2012). The pathogenic mechanisms responsible for nervous system dysfunction in HCV infection are mainly related to up-regulation of host immune responses, with production of autoantibodies, immune complexes and cryoglobulins (Monaco et al., 2012). Accelerated atherosclerosis and cardiovascular disease also occur more frequently in patients with chronic hepatitis C, hypothetically as a result of the persistent activated inflammatory state (Maruyama et al., in press).

Recent findings from the REVEAL-HCV study have highlighted that extrahepatic complications contribute substantially to mortality in chronic hepatitis C patients (Lee et al., 2012). The authors followed 23,820 adults in Taiwan for an average of 16.2 years. HCV antibodies were reactive at baseline in 1095 patients, with serum HCV-RNA detectable in 69.4%. There were 2394 deaths during the study period. As shown in Fig. 1, both liver-related and extrahepatic complications contributed significantly to the nearly 2-fold increase in mortality seen in HCV-seroreactive individuals. Altogether, current knowledge suggests that therapeutic eradication of HCV will result in benefits beyond halting liver injury. Thus, if treatment becomes more efficacious and well tolerated, any infected person should be considered as candidate for therapy, following the roadmap already charted in the HIV/AIDS field (Thompson et al., 2012).

4. The growing public health burden of HCV infection

A more open consideration of the management of chronic hepatitis C has unveiled important gaps that must be filled if advances in therapeutics are to be translated into public health benefits. HCV has surpassed HIV in total annual deaths in the United States (15,000 versus 13,000), but more than half of chronically infected cases have not been diagnosed, largely due to the fact that patients with decompensated liver disease make up less than 10% of the HCV-infected population. In the United States, it is estimated that 2.7–3.9 million people, 1.3–1.9% of the general population, have chronic hepatitis C. The low rate of diagnosis is largely due to the lack of identifiable risk factors for infection in more than half of cases (those termed "*sporadic*") (Rein et al., 2012). This contrast

with HIV, for which most infected persons acknowledge prior risk behaviors. As mentioned, a nationwide campaign for HCV diagnosis in "baby boomers" is currently under way in the US (DHHS, 2012).

The active search for HCV-infected persons through expanded screening should also include younger high-risk groups, such as intravenous drug users. The good news is that new infections have declined over the last two decades, following the introduction of antibody screening tests and harm-reduction campaigns among injecting drug users. Even so, some 18,000 new infections occur in the US each year (Ly et al., 2012). In comparison, there are 50,000 new HIV infections annually, and a total of 1.2 million infected people (0.5% of the population).

5. Advances in diagnostics

Advances in HCV therapeutics have coincided with the arrival of new technologies and diagnostic tools. Two major breakthroughs merit particular recognition. Liver biopsies are no longer required to assess the severity of hepatic damage, as noninvasive tools, including serum fibrosis indices and elastometry (FibroScan), now allow rapid, cheap and accurate assessment of the extent of liver fibrosis. In contrast to liver biopsies, these procedures can be performed repeatedly in the same patient. Given the high cost of DAA, the prioritization of treatment for subjects with significant or advanced liver fibrosis seems justified. However, delaying therapy to cirrhotic stages is penalized by a reduced likelihood of viral clearance and more frequent and severe toxicities. As therapies for hepatitis C become simpler and hopefully cheaper, most if not all patients will be considered to be candidates for treatment, regardless of their liver fibrosis stage and/or co-morbidities (Barreiro et al., 2012).

Another landmark discovery is that a genetic polymorphism in IL28B strongly influences the response to HCV therapy, highlighting the role of innate immunity in the clearance of the virus (Ge et al., 2009; Rallón et al., 2010). This finding suggests that personalized medicine, with genotypic screening preceding drug treatment, will become more common in the near future. Individualization of therapy will include a once-in-a-lifetime baseline assessment, using microarrays, to test for several gene polymorphisms. Treatment decisions will then be based on genetic profiles, including IL28B, ITPA, ENT-2, UGT 1A1, CYP 3A4, LDLr and perhaps HLA DQ*0301 (Soriano, 2012; Soriano et al., 2012).

6. Interferon-free, oral DAA combinations

The current armamentarium against HCV will soon be expanded with molecules belonging to different drug families, including new NS3 protease inhibitors, NS5B polymerase inhibitors (nucleoside and nucleotide analogues and others), and NS5A inhibitors. More than ten drugs are currently completing phase II–III trials, in regimens with or without interferon and/or ribavirin (Table 3) (Lange and Zeuzem, in press; Soriano et al., 2012).

Oral regimens without subcutaneous peginterferon-α are no doubt the most promising, once proof-of-concept testing has

Table 1
Expected effects of antiviral therapy on HIV and HCV infections. ARV: antiretroviral therapy. DAA: direct-acting antivirals.

	ARV (HIV)	DAA (HCV)
Viral replication	Suppression without clearance	Eradication
Major clinical benefit	Reversal of immune deficiency	Reversion of liver fibrosis
Drug-related toxicity	Long lasting, cumulative	Short-term, reversible
Chronic inflammation and persistent immune activation (premature aging)	Amelioration	Elimination
Transmission	Reduction	Elimination

Table 2
Spectrum of clinical complications of chronic hepatitis C.

Hepatic:
- Decompensated cirrhosis
- Liver cancer

Extrahepatic:
- Mucosal & skin diseases: mixed cryoglobulinemia, lichen planus, sicca syndrome, porphyria cutanea tarda, necrolytic acral erythema
- Kidney disease: membranoproliferative glomerulonephritis, diabetic nephropathy
- Neurologic abnormalities: peripheral neuropathy, myasthenia gravis, fatigue, depression
- Cardiovascular disease: atherosclerosis, myocardial injury
- Others: autoimmune thyroiditis, type 2 diabetes, monoclonal gammopathies, B-cell lymphoma


Fig. 1. Risk of death in the REVEAL-HCV study, modified from (Lee et al., 2012). The authors followed 23,820 adults in Taiwan for an average of 16.2 years. HCV antibodies were reactive at baseline in 1095 patients, with serum HCV-RNA detectable in 69.4%. There were 2394 deaths during the study period. Both liver-related and extrahepatic complications contributed significantly to the nearly 2-fold increase in mortality seen in HCV-seroreactive individuals.

Table 3
Direct-acting antivirals for HCV in the most advanced phase II–III trials. Modified from (Lange and Zeuzem, in press).

Protease inhibitors	Nucleoside/ nucleotide analogues	Non-nucleoside polymerase inhibitors	NS5A inhibitors
Boceprevir[a] Telaprevir[a] Simeprevir Faldaprevir ABT-450/r Danoprevir/r Asunaprevir GS-9256	Sofosbuvir Mericitabine IDX-184	ABT-333 BI-7127	Daclatasvir

[a] Already marketed.

shown that they can effectively eliminate HCV. Some combinations should initially be preferred over others. At this time, nucleotide analogues plus either protease inhibitors or NS5A inhibitors appear to be the most attractive. However, the introduction of interferon-sparing regimens has raised several questions, among the most intriguing being the recognition of rare but confirmed late HCV relapses more than 24 weeks after the discontinuation of therapy (Soriano et al., 2012, in press). The possibility of re-infections should always be excluded in this setting.

As oral combination regimens move forward, other questions that must be answered include:

- Why do subtype 1b viruses tend to respond better than subtype 1a? (Rallón et al., 2012; Vispo et al., 2012);
- Which is the shortest successful length of therapy – 12, 16 or 24 weeks?;
- Should treatment always include ribavirin?; and
- Why, and to what extent, does innate immunity (e.g., *IL28B* polymorphism) influence the DAA response?

7. Changing clinical presentations and care of hepatitis C

Several public health implications of the rapid introduction and broad use of DAA can be anticipated (Table 4). First, the use of new HCV drugs will be constrained by cost and the availability of well trained personnel. Second, the benefit of new therapies, in terms of fewer liver decompensation episodes and a reduced need for liver transplantation, will be significant, but only after several years.

Table 4
Public health implications of the widespread use of DAA.

1. Significant increases in cost and demands for the health care system, including well trained personnel
2. Reduced needs for management of hepatic decompensation events and liver transplantation
3. Selection of HCV drug resistance in non-responders
4. Shift in HCV care providers, favoring infectologists over hepatologists
5. Progressive marginalization of residual HCV-infected populations (intravenous drug users, illegal immigrants, alcohol abusers, mentally disabled, etc.)

Fig. 2. Recent and projected changes in medical care for the management of patients infected with HIV (A) and HCV (B). The implementation of new technologies, mainly telemedicine, will favor a shift from hospitals to primary care medicine. ID: infectious disease specialist. GP: general practitioner.

Third, the selection of drug-resistant viruses in patients treated with most of the new DAA will require the design of second-line or rescue regimens, as cross-resistance might jeopardize the success of recycling drugs within the same family. Fourth, we should expect a shift in care providers from hepatologists to infectious disease specialists, due to the new way hepatitis C is managed, targeting asymptomatic cases instead of end-stage liver disease patients, and making decisions based on virological concepts, with which infectologists are more familiar than hepatologists (Soriano et al., 2011a,b).

Finally, economic constraints and limited access to health care will cause a shift in HCV populations, with marginalization of patients. In rich countries, homeless people, illegal immigrants and active intravenous drug users, among others, will not benefit from the new therapies in the short- to mid-term. The high cost of therapy will represent a huge barrier to wide use in resource-limited regions. Unfortunately, we should expect that hepatitis C will gradually become a disease of the very poor. Strategies resembling those implemented for expanding antiretroviral therapy in poor Third World countries with highly endemic HIV must be developed for expanding access to therapies for hepatitis C (Ford et al., 2012).

In the long term, the complexity of oral antiviral therapy will progressively diminish. More potent and simpler HCV drugs, including co-formulations of several molecules (as in the HIV field), given once daily in 1–2 pills, with few drug-drug interactions and convenient safety profiles, will replace first-generation oral HCV antivirals, which still display limited potency, must be given thrice daily, cause frequent drug interactions and are often associated with serious adverse effects. Although the next few years of hepatitis C therapeutics will require significant medical expertise, we can envisage that treatment will become much simpler beyond 3–5 years. Current complex medication regimens, and those soon to be introduced, given with schedules resembling those used for cancer therapy, will steadily be replaced by simpler regimens, perhaps mimicking those now used to treat *Helicobacter pylori*, but for 12 or 24 weeks. As a result, hepatitis C care-givers will shift again from super-specialists to general practitioners.

Fig. 2 records graphically the changes that have occurred and are expected to take place in caring for hepatitis C patients, compared to HIV-infected individuals. The implementation of new technologies, mainly telemedicine, will favor a shift in medical care from hospitals to primary care medicine. For example, a recent study of a rural Veterans Affairs population assessed the impact of HIV and hepatitis C telemedicine consultation on patient outcomes (Saifu et al., 2012). Overall, telemedicine clinics were associated with improved access, greater patient satisfaction and

reductions in health visit time. Similar projects using phone calls or videoconferences have demonstrated the ability of primary care physicians to manage HIV and HCV patients, when they are assisted with easy access to remote specialists (Leon et al., 2011; Arora et al., 2011).

References

Alter, H., Liang, T., 2012. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann. Intern. Med. 156, 317–318.
Arora, S., Thornton, K., Murata, G., 2011. Outcomes of treatment for hepatitis C virus infection by primary care providers. N. Engl. J. Med. 364, 2199–2207.
Barreiro, P., Vispo, E., Labarga, P., Soriano, V., 2012. Management and treatment of chronic hepatitis C in HIV patients. Semin. Liver Dis. 32, 138–146.
Department of Health and Human Services, 2012. Recommendations for the identification of hepatitis C virus chronic infection. CDC Fed. Reg. 77, 30293.
Ford, N., Singh, K., Cooke, G., Mills, E., von Schoen-Angerer, T., Kamarulzaman, A., 2012. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin. Infect. Dis. 54, 1465–1472.
Ge, D., Fellay, J., Thompson, A., Simon, J., Shianna, K., Urban, T., Heinzen, E., Qiu, P., Bertelsen, A., Muir, A., Sulkowski, M., McHutchison, J., Goldstein, D., 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401.
Ghany, M., Nelson, D., Strader, D., Thomas, D., Seeff, L.American Association for Study of Liver Diseases, 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the AASLD. Hepatology 54, 1433–1444.
Lange, C., Zeuzem, S., in press. Perspectives and challenges of interferón-free therapy for chronic hepatitis C. J. Hepatol.
Lee, M., Yang, H., Lu, S., Jen, C., You, S., Wang, L., Wang, C., Chen, W., Chen, C.for the R.E.V.E.A.L.-HCV Study Group, 2012. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J. Infect. Dis. 206, 469–477.
Leon, A., Cáceres, C., Fernández, E., 2011. A new multidisciplinary home care telemedicine system to monitor stable chronic HIV-infected patients: a randomized study. PLoS ONE 6, e14515.
Ly, K., Xing, J., Klevens, R., Jiles, R., Ward, J., Holmberg, S., 2012. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 156, 271–278.
Maruyama, S., Koda, M., Oyake, N., Sato, H., Fujii, Y., Horie, Y., Murawaki, Y., in press. Myocardial injury in patients with chronic hepatitis C infection. J. Hepatol.
Monaco, S., Ferrari, S., Gajofatto, A., Zanusso, G., Mariotto, S., 2012. HCV-related nervous system disorders. Clin. Dev. Immunol. 12, 236148.
Peters, L., Grint, D., Lundgren, J., Rockstroh, J., Soriano, V., Reiss, P., Grzeszczuk, A., Sambatakou, H., Mocroft, A., Kirk, O.for EuroSIDA in EuroCoord, 2012. HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 26, 1917–1926.

Rallón, N., Naggie, S., Benito, J.M., Medrano, J., Restrepo, C., Goldstein, D., Shianna, K., Vispo, E., Thompson, A., McHutchison, J., Soriano, V., 2010. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 24, F23–F29.

Rallón, N., Pineda, J.A., Soriano, V., Neukam, K., Vispo, E., Rivero, A., Labarga, P., Caruz, A., Restrepo, C., Camacho, A., Barreiro, P., Benito, J.M., 2012. Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b. J. Acquir. Immune Defic. Syndr. 60, 117–123.

Rein, D., Smith, B., Wittenborn, J., Lesesne, S., Wagner, L., Roblin, D., Patel, N., Ward, J., Weinbaum, C., 2012. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann. Intern. Med. 156, 263–270.

Saifu, H., Asch, S., Goetz, M., Smith, J., Graber, C., Schaberg, D., Sun, B., 2012. Evaluation of HIV and hepatitis C telemedicine clinics. Am. J. Manag. Care 18, 207–212.

Sarkar, S., Jiang, Z., Evon, D., Wahed, A., Hoofnagle, J., 2012. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C Study. J. Hepatol. 57, 946–952.

Soriano, V., 2012. A new era for hepatitis C – new diagnostic tools and new weapons. ACS Med. Chem. Lett. 7, 345–346.

Soriano, V., Sherman, K., Rockstroh, J., Dieterich, D., Back, D., Sulkowski, M., Peters, M., 2011a. Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-coinfected patients. AIDS 25, 2197–2208.

Soriano, V., Vispo, E., Poveda, E., Labarga, P., Martin-Carbonero, L., Fernandez-Montero, J.V., Barreiro, P., 2011b. Directly acting antivirals against hepatitis C virus. J. Antimicrob. Chemother. 66, 1673–1686.

Soriano, V., Poveda, E., Vispo, E., Labarga, P., Rallón, N., Barreiro, P., 2012. Pharmacogenetics of hepatitis C. J. Antimicrob. Chemother. 67, 523–529.

Soriano, V., Vispo, E., Barreiro, P., in press. Hepatitis C therapeutics – highlights from EASL 2012. Clin. Infect. Dis.

Thompson, M., Aberg, J., Hoy, J., Telenti, A., Benson, C., Cahn, P., Eron, J., Günthard, H., Hammer, S., Reiss, P., Richman, D., Rizzardini, G., Thomas, D., Jacobsen, D., Volberding, P., 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308, 387–402.

Vispo, E., Rallon, N., Labarga, P., Barreiro, P., Benito, J.M., Soriano, V., 2012. Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J. Clin. Virol. 55, 58–61.